SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-010384
Filing Date
2021-08-05
Accepted
2021-08-05 07:15:45
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20210805x8k.htm   iXBRL 8-K 45702
2 EX-99.1 acrs-20210805xex99d1.htm EX-99.1 180924
3 GRAPHIC acrs-20210805xex99d1001.jpg GRAPHIC 29882
  Complete submission text file 0001558370-21-010384.txt   402293

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20210805.xsd EX-101.SCH 2984
5 EX-101.LAB acrs-20210805_lab.xml EX-101.LAB 16066
6 EX-101.PRE acrs-20210805_pre.xml EX-101.PRE 10373
7 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20210805x8k_htm.xml XML 4798
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 211146284
SIC: 2834 Pharmaceutical Preparations